Aurora develops an R&D B2B enterprise service SaaS platform for life science clinical research. The company aims to empower the data analysis and operation management of life science research and development, and to accelerate the commercialization of original research drugs and new medical devices. It was founded in 2020 and is based in Shanghai, China.
Missing: Aurora's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
ESPs containing Aurora
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
These companies offers solutions that capture and store patient data electronically during clinical trials, eliminating the need for paper documentation. These solutions enable faster downstream processes by ensuring that data is cleaner and easier to access.
Missing: Aurora's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Aurora
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aurora is included in 4 Expert Collections, including Clinical Trials Tech.
Clinical Trials Tech
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Clinical Trials Tech Market Map
This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.
Latest Aurora News
Oct 6, 2022
Newton, Massachusetts, UNITED STATES $3 million awarded to University of North Carolina (UNC) to support a proposed 180-patient, randomized, placebo-controlled trial in trauma patients Proposed investigator sponsored trial to evaluate the potential for ACER-801 to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD) Up to 20% of people who have experienced a traumatic event will develop PTSD1 leading to over 12 million adults in the US suffering from PTSD during a given year2 NEWTON, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the University of North Carolina (UNC) Institute for Trauma Recovery has been awarded a $3 million grant from the Department of Defense (DoD) to investigate the potential of ACER-801 (osanetant) to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD). Acute stress disorder refers to the body’s immediate response to trauma, whereas PTSD is the long-term effects of trauma. “Historically, we have been able to provide emergency care to address immediate and long-term problems after visible wounds using tools such as sutures and antibiotics. However, we still have nothing to offer trauma survivors, whether in the emergency department or on the battlefield immediately after trauma, to prevent the development of ‘invisible wounds’,” said Samuel McLean, MD, Professor at UNC, School of Medicine, and lead principal investigator of the proposed study. Dr. McLean continued, “We need to investigate potential treatments like ACER-801 in an effort to better address these challenges.” The proposed Osanetant After Stress to Increase recovery Success (OASIS) trial will examine the safety and efficacy of ACER-801 to reduce acute stress response symptoms, post-traumatic stress disorder symptoms and behavioral changes among patients presenting to the emergency department after a motor vehicle collision. It is intended to enroll a total of 180 subjects who will be randomized in the emergency department, to receive a low or high dose of ACER-801 or placebo in the emergency department and be discharged with a two-week supply of study drug. Participating sites would include Washington University in St. Louis, University of Massachusetts Chan Medical School, Rhode Island Hospital, University of Florida College of Medicine – Jacksonville, and Indiana University School of Medicine. Initiation of patient enrollment in the proposed investigator sponsored OASIS trial is anticipated in the first half of 2023, subject to Investigational New Drug (IND) application filing and U.S. Food and Drug Administration (FDA) clearance. The OASIS trial will build upon a foundation of knowledge and infrastructure developed through the UNC-led, $40 million AURORA initiative. The AURORA study is a major national research initiative to improve the understanding, prevention, and recovery of individuals who have experienced a traumatic event. AURORA is supported by funding from NIH, One Mind, private foundations, and partnerships with leading tech companies such as Mindstrong Health and Verily Life Sciences, the health care arm of Google’s parent company Alphabet. “We are proud to be partnering with a leading academic institution in the field of trauma recovery as we seek to explore ACER-801 as a treatment option to reduce the frequency and severity of PTSD. Leveraging the support from the AURORA initiative allows Acer and UNC to streamline trial efficiency, reduce costs and increase trial power through enriching the target patient population, while utilizing the Department of Defense’s non-dilutive capital to primarily fund OASIS,” said Adrian Quartel, MD, FFPM, Chief Medical Officer of Acer. “The data from thousands of motor vehicle collisions collected through the AURORA initiative should allow us to better predict the correlation of the emergence of acute stress disorder or PTSD symptoms following a motor vehicle collision. We look forward to the planned OASIS trial following IND filing and FDA clearance.” Added Brandon Staglin, President of One Mind “We are thrilled to see how our funding to the AURORA initiative over the last five years is accelerating further advancements such as the OASIS Trial. The targeted outcomes of the OASIS Trial are the types of results that One Mind supports and of incredible value to anyone who experiences trauma and traumatic stress.” Acute and chronic stress disorders can affect both civilian and military populations. According to the National Center for PTSD, in the US about 60% of men and 50% of women experience at least one trauma in their lives.2 In the US alone, one-third of emergency department visits (40-50 million patients per year) are for evaluation after trauma exposures, and in a 2014 study involving 3,157 US veterans, 87% reported exposure to at least one potentially traumatic event during their service.3 Moreover, as many as 500,000 US troops who served in wars between 2001 and 2015 were diagnosed with PTSD.4 Rationale for ACER-801 (osanetant) Evaluation in Post-Traumatic Stress Disorder. The Tacr3 gene encodes tachykinin receptor 3 (NK3R), which belongs to the tachykinin receptor family. This family of proteins includes typical G protein-coupled receptors and belongs to the rhodopsin subfamily. NK3R functions by binding to its high-affinity ligand, Neurokinin B (NKB), which is encoded by the Tac3 (human) gene. The role of NKB-NK3R in growth and reproduction has been extensively studied, but NKB-NK3R is also widely expressed in the nervous system from the spinal cord to the brain and is involved in both physiological and pathological processes in the nervous system.5 In animal models, Tac2 (mice) mRNA levels are rapidly up-regulated during fear consolidation 30 minutes after fear conditioning, and subsequent NKB-NK3R activation can lead to over stress sensitization and the consolidation of fear,6 and treatment with osanetant has been shown to block a critical fear/stress sensitization step in the brain.7,8,9 An effective therapeutic to reduce acute and persistent/long-term psychological and somatic symptoms would fulfill a large unmet need. About Acer Therapeutics Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four investigational programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS) and post-traumatic stress disorder (PTSD); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, Zika, dengue, Ebola and COVID-19. For more information, visit www.acertx.com . References
Aurora Web Traffic
Aurora Frequently Asked Questions (FAQ)
When was Aurora founded?
Aurora was founded in 2020.
Where is Aurora's headquarters?
Aurora's headquarters is located at Room 1515, Block B, 1188 Kaixuan North Road, Shanghai.
What is Aurora's latest funding round?
Aurora's latest funding round is Series A - II.
How much did Aurora raise?
Aurora raised a total of $15.45M.
Who are the investors of Aurora?
Investors of Aurora include Hankang Equity Investment Management, B Capital Group, Lightspeed China Partners, Shanghai Artificial Intelligence Industry Investment Fund, Primavera Capital Group and 3 more.
Who are Aurora's competitors?
Competitors of Aurora include Dacima Software, Protocol First, Prelude Dynamics, Castor EDC, BioClinica and 10 more.
Compare Aurora to Competitors
MedNet Solutions is a healthcare technology company, specializing in electronic data capture (EDC) and clinical study management systems designed for the global life sciences industry. The company's cloud-based, EDC/eclinical platform allows non-technical sponsors and CRO personnel to build their own clinical studies through a customizable, clinical study management solution delivering complete EDC, CTMS, and CDMS functionality.
RodanoTech provides clinical data management services and EDC solutions. The company offers solid data management and EDC services, investigator focused clinical trial solutions, an online medical community platform, and e-Solutions for the post-approval market. It is based in Geneva, Switzerland.
Clinical Ink is dedicated to transforming clinical development – from Start to Submit – by creating a completely 'paperless' clinical trial platform. Clinical Ink's SureSource platform is purpose-built to capture source data and documents electronically for sites, sponsors, CROs and patients.
Prelude Dynamics offers flexible Electronic Data Capture and Clinical Trial Management System for clinical trials in human and animal health.
OpenClinica is open source, web-based clinical trials software for electronic data capture (EDC) and clinical data management (CDM). OpenClinica facilitates data collection via electronic case report forms (eCRFs), lab data import, and provides tools for data management and productive monitoring of clinical trials.
Castor EDC specializes in electronic data capture for medical research. It aims to take the clinical trial process which it describes as largely being offline and paper-based and digitizes it via software.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.